Future studies need to extend these analyses to other breast cancer models, and to investigative the efficacy of combining standard-of-care chemotherapies with c-Abl-targeted therapies as a specific strategy to eliminate TNBCs that house mutant p53. The gene discussed is ABL1; the disease is breast carcinoma.